CStone Pharmaceuticals
CStone Pharmaceuticals Fundamental Analysis
CStone Pharmaceuticals (2616.HK) shows weak financial fundamentals with a PE ratio of -41.01, profit margin of -1.24%, and ROE of -64.19%. The company generates $0.2B in annual revenue with weak year-over-year growth of -12.21%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -145.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 2616.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak2616.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate2616.HK shows balanced valuation metrics.
Growth Score
Moderate2616.HK shows steady but slowing expansion.
Financial Health Score
Excellent2616.HK maintains a strong and stable balance sheet.
Profitability Score
Weak2616.HK struggles to sustain strong margins.
Key Financial Metrics
Is 2616.HK Expensive or Cheap?
P/E Ratio
2616.HK trades at -41.01 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 2616.HK's PEG of 2.81 indicates potential overvaluation.
Price to Book
The market values CStone Pharmaceuticals at 19.88 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -45.88 times EBITDA. This is generally considered low.
How Well Does 2616.HK Make Money?
Net Profit Margin
For every $100 in sales, CStone Pharmaceuticals keeps $-1.24 as profit after all expenses.
Operating Margin
Core operations generate -1.21 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-64.19 in profit for every $100 of shareholder equity.
ROA
CStone Pharmaceuticals generates $-22.01 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
CStone Pharmaceuticals generates limited operating cash flow of $-149.19M, signaling weaker underlying cash strength.
Free Cash Flow
CStone Pharmaceuticals generates weak or negative free cash flow of $-149.19M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.10 in free cash annually.
FCF Yield
2616.HK converts -1.33% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-41.01
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
2.81
vs 25 benchmark
P/B Ratio
Price to book value ratio
19.88
vs 25 benchmark
P/S Ratio
Price to sales ratio
48.63
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.57
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.18
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.64
vs 25 benchmark
ROA
Return on assets percentage
-0.22
vs 25 benchmark
ROCE
Return on capital employed
-0.34
vs 25 benchmark
How 2616.HK Stacks Against Its Sector Peers
| Metric | 2616.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -41.01 | 28.31 | Better (Cheaper) |
| ROE | -64.19% | 699.00% | Weak |
| Net Margin | -124.02% | -130884.00% (disorted) | Weak |
| Debt/Equity | 0.57 | 0.34 | Weak (High Leverage) |
| Current Ratio | 2.18 | 2775.16 | Strong Liquidity |
| ROA | -22.01% | -14469.00% (disorted) | Weak |
2616.HK outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews CStone Pharmaceuticals's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
0.00%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
97.98%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
78.46%
Industry Style: Defensive, Growth, Innovation
High Growth